Anthropic's Mithril acquisition signals push into AI-driven drug discovery

Anthropic acquired one-man firm Mithril as part of a broader effort to use AI to accelerate drug development, while seeking a $1.4 trillion valuation in the public markets.

Read the full story at Forbes AI ↗

Timeline · 1 report

2026-11-11 14:00 · Forbes AI
Anthropic’s Drug Discovery Dreams: ‘It Is Not A Side Effort’

More stories

Anthropic targets $1.4 trillion valuation in IPO as demand surges — CNBC Technology
Did Claude Code’s ‘don’t ask again’ option accidentally expose your enterprise's passwords and keys? — VentureBeat AI
OpenAI's quarterly revenue rises 50% to $10 billion, but operating losses widen — The Information AI
DeepSeek's Harness agent app reaches 1.54 million daily users — Bloomberg AI
Anthropic's I.P.O. and the Clubby Business of A.I. — New York Times Technology
Anthropic’s Mega-IPO Is Said to Be Multiple Times Oversubscribed — Bloomberg AI
Cognizant Launches Claude Managed Services With 25,000-Strong Frontier Capability Group — Economic Times Tech
Daily AI briefings track Claude office-suite push, new TPUs and national AI policy — DEV Community — Machine Learning

Get the daily brief of stories like this at 6:30 every morning →